Verolet Charlotte M, Posfay-Barbe Klara M
Pediatric Infectious Diseases Unit, Division of General Pediatrics, Department of Pediatrics, University Hospitals of Geneva & University of Geneva Medical School, Geneva, Switzerland,
Curr Infect Dis Rep. 2015 Apr;17(4):472. doi: 10.1007/s11908-015-0472-y.
Solid organ and hematopoietic stem cell transplant recipients may be exposed to diseases which may be prevented through live attenuated virus vaccines (LAVV). Because of their immunosuppression, these diseases can lead to severe complications in transplant recipients. Despite increasing evidence regarding the safety and effectiveness of certain LAVV, these vaccines are still contraindicated for immunocompromised patients, such as transplant recipients. We review the available studies on LAVV, such as varicella zoster, measles-mumps-rubella, influenza, yellow fever, polio, and Japanese encephalitis vaccines in transplant patients. We discuss the current recommendations and the potential risks, as well as the expected benefits of LAVV immunization in this population.
实体器官和造血干细胞移植受者可能会接触到一些可通过减毒活疫苗（LAVV）预防的疾病。由于他们处于免疫抑制状态，这些疾病可能会在移植受者中引发严重并发症。尽管越来越多的证据表明某些LAVV具有安全性和有效性，但这些疫苗仍被禁止用于免疫功能低下的患者，如移植受者。我们回顾了关于LAVV的现有研究，如移植患者中的水痘带状疱疹、麻疹-腮腺炎-风疹、流感、黄热病、脊髓灰质炎和日本脑炎疫苗。我们讨论了当前的建议、潜在风险，以及在这一人群中进行LAVV免疫接种的预期益处。
